Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…